05:19 PM EDT, 06/12/2025 (MT Newswires) -- Silence Therapeutics ( SLN ) said Thursday updated phase 1 trial data reinforced safety profile, efficacy and dosing convenience of divesiran as a potential treatment for polycythemia vera.

"Divesiran continues to demonstrate a very compelling profile as the first-in-class siRNA for PV," said CEO Craig Tooman.

"The Phase 2 study is over 50-percent enrolled, and we remain on-track to complete patient enrollment by the end of this year."

The data were presented at the European Hematology Association 2025 Annual Meeting in Milan, Italy, the company said.

Shares were up over 4% in after-hours trading.